Bristol-Myers Squibb Company (BMY) Enterprise Value (EV): $147.02B
The enterprise value (EV) for Bristol-Myers Squibb Company (BMY) is $147.02B as of Wednesday, June 10, 2026.
BMY Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$147.02B
BMY Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $114.14B | $147.02B |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | $114.72B |
| CVS Health Corporation (CVS) | $125.16B | $185.63B |
| Medtronic plc (MDT) | $103.04B | $106.80B |
| Danaher Corporation (DHR) | $130.25B | $175.72B |
| Elevance Health Inc. (ELV) | $87.43B | $101.50B |
| Pfizer Inc. (PFE) | $146.36B | $207.77B |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | $199.07B |
| Cigna Corporation (CI) | $78.25B | $96.98B |
| Gilead Sciences, Inc. (GILD) | $151.21B | $169.72B |
Enterprise Value Calculation
Market Cap
$114.14B
Total Debt
$45.11B
Cash
$10.21B
Enterprise Value
$147.02B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Bristol-Myers Squibb Company Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Bristol-Myers Squibb Company (BMY)?
- The enterprise value (EV) for BMY stock is $147.02B.
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner